PHEnotyping type 2 inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP) using RHeology of sinonasal secretions and tissue EOsinophil mapping in the middle turbinate

The human nose is more than a gateway for air; it is a complex ecosystem where the body's defenses constantly interact with the environment. In some people, this system becomes stuck in a state of high alert, leading to a condition called chronic rhinosinusitis with nasal polyps. This is not merely a bad cold that won't go away; it is a persistent inflammation where the lining of the nose swells and grows into soft, grape-like masses known as polyps. For many, this condition is driven by a specific type of immune response, often linked to asthma and allergies, where the body produces an excess of white blood cells called eosinophils. These cells, while meant to fight parasites, can damage the delicate tissues of the nose when they accumulate in large numbers. Doctors have powerful new medicines, known as biologics, that can calm this specific immune overreaction. However, these treatments are expensive and do not work for everyone. The medical community is currently searching for better ways to predict which patients will respond to these drugs, moving beyond simple blood tests to find clues hidden directly within the nose itself.

In a new study conducted at the University Hospital in Montpellier, France, researchers are testing a fresh approach to this puzzle by looking at the physical nature of the mucus itself. The team, led by Valentin Favier and colleagues, is conducting a study called PheRhEos. Their central idea is that the mucus produced by inflamed noses might have different physical properties than mucus from healthy noses, much like how honey flows differently than water. Specifically, they are investigating whether the thickness and stretchiness of the mucus can reveal the level of inflammation inside. This concept is not entirely new; in lung diseases, doctors have long observed that mucus from patients with high levels of eosinophils tends to be thicker and more resistant to flow. The researchers hypothesize that the same rule applies to the nose and that measuring these physical traits could serve as a rapid, local biomarker to help identify the most severe cases of the disease.

To test this, the team is enrolling sixty adults who are already scheduled for surgery at their hospital. Thirty of these participants have chronic rhinosinusitis with nasal polyps, while the other thirty serve as a control group. These control patients are undergoing surgery for non-inflammatory reasons, such as correcting a deviated septum or treating sleep apnea, meaning their noses do not suffer from the same chronic inflammation. The study is designed to be straightforward and practical. During the pre-surgery period, participants will blow their noses onto a sterile plate to collect a sample of their natural, undiluted secretions. This sample is then immediately analyzed using a specialized device called a Rheomuco. This machine gently stretches and squeezes the mucus to measure its viscous modulus, which is a scientific way of describing how much the liquid resists flowing, and its elastic modulus, which measures how well it bounces back after being stretched. The researchers are looking for a distinct difference in these numbers between the patients with polyps and those without.

While the mucus is being analyzed for its physical properties, the study also digs deeper into the tissue itself. During the surgery, the surgeons will collect small pieces of tissue from the middle turbinate, a structure inside the nose that is often removed or biopsied during these procedures. The researchers will examine these tissue samples under a microscope to count the exact number of eosinophils present. They will also look for specific proteins on the surface of these cells, such as the receptor for interleukin-5, a chemical signal that tells eosinophils to grow and survive. By mapping where these cells are located within the tissue, the team hopes to understand if the inflammation is spread evenly or if it is concentrated in specific spots, which could explain why some standard biopsies might miss the severity of the disease.

The study is not just about comparing the two groups; it is also about connecting the dots between different types of data. The researchers will correlate the physical measurements of the mucus with the number of eosinophils found in the tissue, as well as with standard blood tests and breathing measurements that patients might already have. They are also collecting the mucus samples for further analysis in a laboratory, where they will look for specific proteins and sugars that make up the mucus, such as mucins, which are the building blocks that give mucus its gel-like structure. The goal is to see if a thick, sticky mucus is always accompanied by a high count of eosinophils and high levels of inflammatory signals in the blood.

This research is a prospective study, meaning the team is following a plan set out in advance to gather data as events happen, rather than looking back at old records. The study is scheduled to run until the sixty participants are fully enrolled and analyzed. The researchers have calculated that they need at least twenty-eight people in each group to be confident in their results, so they are aiming for thirty per group to account for any samples that might be lost or unusable. The primary question they are trying to answer is simple: does the mucus from a nose with polyps flow differently than the mucus from a nose without them? If the answer is yes, and if that difference is linked to the amount of inflammation, then this method could become a new tool for doctors. It would offer a way to look directly at the disease in the nose, rather than relying solely on blood tests that might not fully reflect what is happening locally.

The study acknowledges that it has limitations. It is being conducted at a single hospital, and the control group consists of people undergoing surgery for other reasons, not healthy volunteers from the general population. This means the results might need to be confirmed in a larger, more diverse group of people before they can be used as a standard test. Furthermore, this study is a snapshot in time; it compares patients before surgery but does not yet track how they respond to treatment over time. The researchers are careful to state that their work is a step toward a solution, not the final answer. They are not claiming to have solved the problem of choosing the right medicine for every patient, but rather that they are testing a new method to see if it holds promise.

If the results show a clear link between the physical properties of the mucus and the local inflammation, it could change how doctors approach the disease. Currently, treatment decisions are often based on the severity of symptoms, the history of past surgeries, and broad markers found in the blood. A test that could quickly measure the physical state of the mucus in a clinic, without needing complex lab work, would be a significant advance. It would allow doctors to see the "texture" of the inflammation, potentially identifying patients who have a high burden of eosinophils even if their blood tests appear normal. This could lead to more personalized care, ensuring that the right patients receive the right biologics sooner, while sparing others from unnecessary treatments.

The PheRhEos study represents a shift in how scientists view the nose. Instead of seeing it only as a collection of cells and chemicals, they are beginning to treat it as a material with physical properties that tell a story about the body's immune state. By combining the measurement of mucus flow with the microscopic counting of immune cells, the researchers are building a more complete picture of chronic rhinosinusitis. Their work suggests that the answer to better treatment might lie not just in the chemistry of the disease, but in its physics. As the data is collected and analyzed, the medical community will learn whether the way mucus flows can truly guide the way doctors heal.